drugset / Trial / NCT00987870

Safety and Efficacy of BFH772 in Psoriasis Patients

NCT00987870

Phase 1/2 Completed 15 enrolled Novartis Pharmaceuticals
RandomizedSingle-groupTriple-blindTreatment

Summary

This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.

Timeline

Start
2009-09
Primary completion
2010-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BFH772 Small molecule 1 % Topical
Comparator Betamethasone Other / unclassified Topical
Comparator Calcipotriol Small molecule Topical